Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Regulation 52

Regulation Vaccination Vaccine Trials 52

pharmaphorum

JANUARY 26, 2023

2022 was a banner year for genomics. In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA.

Genome 129

Genome Genomics Genome Project Genetics 129

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says.

Genome 105

Genome Genomics Medicine Development 105

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . This process requires the sequence of the viral protein, which can be determined from its genome and is then coupled with an optimised ‘clamp’ sequence. The University of Queensland. .

Vaccination 52

Vaccination Vaccine Immune Response Engineer 52

Drug Discovery World

APRIL 10, 2023

India is traditionally known as ‘the pharmacy of the world’ due to its huge pharmaceuticals manufacturing capacity and high quantity of exports, particularly generic medicines and vaccines. Hyderabad is recognised as the vaccine hub of India. India’s domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 2.

Genome 52

Genome Genomics Drugs Life Science 52

Pharmaceutical Technology

SEPTEMBER 22, 2022

You have just received the results from your whole genome sequencing test, offered through your public health provider, and discovered that you have a 75% chance of developing a rare form of cancer. It could be that you are lucky, and there is already a cancer vaccine on the market that you will get priority for. It is the year 2030.

Genome 342

Genome Genomics Clinical Trials Clinical Trials 342

The Pharma Data

DECEMBER 2, 2020

” VANCOUVER, BC, December 02, 2020 /24-7PressRelease/ — Eyam Vaccines and Immunotherapeutics (EYAM) today announced that former President and CEO of Genome Prairie is joining EYAM. Additional information about Dr. Pontarollo advancement of research projects at Genome Prairie can be found here: [link] … -at-u-of-s.

Vaccination 52

Vaccination Vaccine Genome Genomics 52

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Manufacturing 246

Manufacturing Vaccination Vaccine Gene Therapy 246

Drug Discovery World

AUGUST 16, 2023

The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. Decoding ‘junk DNA’ The Human Genome Project and subsequent studies discovered that most of our DNA (approximately 98%) does not actually code for proteins, with humans having approximately 20,000 tox 25,000 protein-coding genes.

RNA 52

RNA Genome Genomics DNA 52

BioPharma Reporter

APRIL 16, 2024

Cytiva has announced the launch of its Xcellerex magnetic mixer â a single-use mixing system designed to address challenges faced by customers engaged in large-scale mAb, vaccine and genomic medicine manufacturing processes.

Genome 52

Genome Genomics Manufacturing Vaccination 52

Scienmag

NOVEMBER 16, 2020

The genomic surveillance system will help public health authorities detect and respond to local outbreaks faster and monitor for viral mutations associated with escape from vaccines once they are deployed The Department for Health and Social Care Testing Innovation Fund has backed the Wellcome Sanger Institute and the COVID-19 Genomics UK (COG-UK) (..)

Genome 42

Genome Genomics Vaccination Vaccine 42

The Pharma Data

DECEMBER 14, 2020

ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. Both vaccines have demonstrated about 94-95% efficacy in clinical trials.

Vaccination 52

Vaccination Vaccine Allergies Genome 52

Drug Discovery World

JANUARY 11, 2024

They are called: mRNA technology may hold the future for a cytomegalovirus vaccine ; Predictive diagnostics: closing the precision medicine gap ; and FAIR Game: making data work harder in the race to market. In the first article, Allison August, M.D., In the first article, Allison August, M.D.,

Development 59

Development Drugs Genome Genomics 59

The Pharma Data

JANUARY 11, 2021

health officials raced to ramp up the delivery of COVID-19 vaccines across the country as both coronavirus case counts and death tallies continued to hit record highs. “We really need to get this vaccine out more quickly, because this is really our only tool,” Dr. Scott Gottlieb, former commissioner of the U.S. .

Vaccination 52

Vaccination Vaccine Nurses Genome 52

STAT News

FEBRUARY 22, 2023

Moderna is aiming to build a gene editing franchise powered by some of the same technologies used in its COVID-19 vaccines. Moderna will fund preclinical research studies run by the two companies using Life Edit’s tools based on CRISPR technologies that allow scientists to make precise changes to the human genome.

Gene Editing 126

Gene Editing Gene Genetic Disease Research 126

The Pharma Data

JANUARY 26, 2021

offered its genomics expertise to identify emerging variants of the SARS-CoV-2 virus to countries that lack the resources to make such identifications. has carried out more than half of all SARS-CoV-2 genome sequences submitted to the global database. On Tuesday, the U.K. The offer came as part of the U.K.’s South Africa and Brazil.

Genome 52

Genome Genomics Vaccination Vaccine 52

The Pharma Data

JULY 6, 2021

He and his team reasoned that the virus would likely mutate, potentially in ways that would allow it to escape both natural and vaccine-induced immunity. These epitopes could then be used in a vaccine to train T cells, providing protective immunity. The team obtained sequences from the newly circulating B.1.1.7

Vaccination 52

Vaccination Vaccine Research Immune Response 52

STAT News

NOVEMBER 3, 2022

Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-19 vaccines, and lifesaving medicines could run aground if humanity can’t get out of its own way. Read the rest…

Genome 98

Genome Genomics Clinical Trials Clinical Trials 98

The Pharma Data

DECEMBER 10, 2020

–( BUSINESS WIRE )– ImmunityBio , a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. 11, 2020 02:48 UTC. CULVER CITY, Calif.–(

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

BioSpace

NOVEMBER 15, 2021

This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.

Gene Editing 75

Gene Editing Life Science Genome Genomics 75

Drug Discovery World

DECEMBER 19, 2023

What you will learn: How advances in technology have accelerated drug development How AI can address key bottlenecks in the drug discovery process Which technological advancements are likely to have the greatest impact The role of new technology in the post-launch phase How technology is enabling quicker and more comprehensive characterisation of vaccine (..)

Vaccination 64

Vaccination Vaccine Genome Genomics 64

STAT News

SEPTEMBER 30, 2022

The shortlist includes researchers who elucidated how cells make energy, those who discovered the chemical chatter of bacteria, many of the brilliant minds who shepherded us into the “ era of the genome ,” and most prominently, the pioneers behind the mRNA Covid vaccines. Read the rest…

Bacteria 124

Bacteria Genome Genomics Vaccination 124

The Pharma Data

MARCH 7, 2022

Decision Regarding Slick-Haired Cattle is Agency’s First Enforcement Discretion Decision for an Intentional Genomic Alteration in an Animal for Food Use. IGAs are alterations made using molecular technologies that introduce changes to the genome of an animal. Today, the U.S. Solomon, D.V.M., Related Information.

Genome 52

Genome Genomics Production Marketing 52

pharmaphorum

JANUARY 5, 2023

and OriCiro Genomics K.K. The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. Biotech Moderna, Inc.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97

pharmaphorum

NOVEMBER 28, 2021

1.1.529 variant of COVID-19 – now christened Omicron – leading vaccine manufacturers have said they are poised to develop new shots if needed. Other vaccine manufacturers have also responded to the new variant. With governments around the world announcing measures to curb the new B.1.1.529

Vaccination 111

Vaccination Vaccine Protein Genetics 111

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Vaccination 111

Delveinsight

DECEMBER 15, 2020

Pfizer, BioNTech COVID-19 Vaccine rolls out in a watershed moment. In a historic first, the US FDA issued an Emergency Use Authorization (EUA) to the COVID-19 mRNA, BNT162b2, vaccine candidate for COVID-19 of Pfizer-BioNTech. The vaccine is the first-ever mRNA vaccine to get to the EUA and is developed in record-time low.

Vaccination 54

Vaccination Vaccine Gene Therapy Gene 54

Drug Discovery World

JANUARY 11, 2024

They are called: mRNA technology may hold the future for a cytomegalovirus vaccine ; Predictive diagnostics: closing the precision medicine gap ; and FAIR Game: making data work harder in the race to market. In the first article, Allison August, M.D., In the first article, Allison August, M.D.,

Development 52

Development Drugs Genome Genomics 52

XTalks

DECEMBER 17, 2021

The year continued to be dominated by COVID-19, and the second year of the pandemic was all about vaccines. And while over 8 billion doses of vaccines have been administered worldwide, billions more are still needed. And while over 8 billion doses of vaccines have been administered worldwide, billions more are still needed.

Life Science 98

Life Science Vaccination Vaccine Trials 98

Drug Discovery World

JULY 22, 2022

Covid-19 vaccines remain effective six months after second dose . Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.? . An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection.? .

DNA 52

DNA Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 9, 2023

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. . The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. .

Research 52

Research Vaccination Vaccine Trials 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive. Targeted drug combo attacks breast cancer brain metastases in mice.

Vaccination 53

Vaccination Vaccine Research Trials 53

STAT News

JANUARY 20, 2023

Support for it gained traction as the Covid-19 pandemic highlighted concerns about global vaccine inequity, genomic data-sharing, and more. The December talks productively focused on these issues and concluded with delegates agreeing to another round of negotiation in February.

Genome 119

Genome Genomics Vaccination Vaccine 119

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR nucleases serve as an important genome editing tool.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

Pharmaceutical Technology

JUNE 20, 2023

The proposed institute will focus on vaccine research, public health research, therapeutics, genomics, diagnostics, clinical trials and data. It will be connected across multiple levels to the University of Melbourne’s Doherty Institute.

Biobanking 130

Biobanking Genome Genomics Clinical Trials 130

pharmaphorum

AUGUST 10, 2020

The data mining tool will be used to try to unearth some of the many unknowns with the virus, using next-generation sequencing (NGS) to see how the genome of SARS-CoV-2 changes over time, along with patient genetic information, results of lung and CT scans, and other clinical data.

Genetics 136

Genetics Genome Genomics Vaccination 136

Drug Discovery World

JANUARY 21, 2024

As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.

Protein 52

Protein Vaccination Vaccine Development 52